Kidney Week Educational Symposia-Basics to Bedside: State-of-the-Art Rationale and Approach to Hyperkalemia in Kidney Diseases

Video Transcription

Video Summary

The session introduces hyperkalemia by linking how potassium is measured, sensed, and regulated to clinical risk across kidney disease populations. The speaker first reviews laboratory measurement: older flame photometry (light emission from excited ions) has largely been replaced by ion‑selective electrodes, and emphasizes learning from laboratory practices and artifacts. Physiologically, potassium is “sensed” in the adrenal zona glomerulosa via potassium-channel–mediated depolarization that raises intracellular calcium and increases aldosterone. In the distal convoluted tubule, hyperkalemia alters membrane potential and chloride/WNK signaling to reduce NCC activity, increase distal sodium delivery, and—together with aldosterone—promote potassium secretion downstream.<br /><br />Dr. Navaneethan then summarizes epidemiology: hyperkalemia risk rises sharply as eGFR declines, and serum potassium shows U‑shaped associations with mortality and cardiovascular outcomes. Many episodes are detected in the community. High-risk groups include older adults (with frequent recurrence), CKD, heart failure, RAS inhibitor and NSAID users, dialysis patients (both hyper- and post-dialysis hypokalemia concerns), and transplant recipients (notably calcineurin inhibitors and prophylactic antimicrobials). Racial differences exist in potassium distributions, though outcome patterns are broadly similar.<br /><br />Dr. Klass reviews outpatient management: mechanisms in the aldosterone-sensitive nephron, medication causes, and pseudohyperkalemia (e.g., fist clenching). She stresses unclear outpatient action thresholds and recommends minimizing contributors, reassessing indications for RASi/MRAs, using diuretics, cautious diet counseling, considering binders (effective but costly, limited outcome data), and using SGLT2 inhibitors which reduce hyperkalemia-related events while improving clinical outcomes.

Asset Subtitle

Moderators: Melanie Hoenig

Speakers:

- Introduction - Melanie Hoenig
- Potassium Dysregulation Among Diverse Patient Populations with Kidney Diseases - Sankar Navaneethan
- The Physiology of Hyperkalemia and Its Treatments - Catherine Clase

Meta Tag

Date 11/5/2021

Pathway 1 Hypertension and CVD

Pathway 2 Bone and Mineral Metabolism

Session ID 408976

Session Type ES - Educational Symposium

Keywords

hyperkalemia

potassium measurement

ion-selective electrode

aldosterone regulation

adrenal zona glomerulosa

distal convoluted tubule

chronic kidney disease

renin-angiotensin system inhibitors

outpatient management